MTMegan M. Tu

Megan M. Tu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Megan M. Tu has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Electrostatic Modulation of Antibiotic Susceptibility by the Bacterial Donnan Potential

    by Maya A. Farha, Megan M. Tu, Rodion Gordzevich, Kenneth Rachwalski, Eric D. Brown

    Antibiotic resistance in Gram-negative bacteria is a major global health threat, in part because of the permeability barriers of their double-membrane envelope and active efflux systems. While porins, lipopolysaccharides, and efflux pumps have been extensively studied, the role of membrane energetics, particularly the Donnan potential (DP), in antibiotic susceptibility remains poorly understood. The DP arises from negatively charged osmoregulated periplasmic glucans (OPGs), which generate an electrostatic potential in the periplasm that is capable of influencing how molecules traverse the outer membrane. Here, we systematically examine how OPG-dependent electrostatic changes associated with the DP shape antibiotic susceptibility in Escherichia coli. By altering the environmental osmolarity, we generated conditions that changed OPG abundance and were expected to alter associated periplasmic electrostatics, revealing that low-salt conditions enhance the potency of cationic antibiotics but reduce the activity of anionic compounds, whereas high-salt conditions or OPG deficiency attenuate cationic drug activity. Strains producing neutral OPGs phenocopied OPG-deficient mutants, implying that the OPG charge is involved in this effect. Clinical E. coli isolates varied in sensitivity to osmolarity- and OPG-dependent electrostatic effects, and similar trends were observed across multiple Gram-negative pathogens. Finally, we show that dietary salt intake modulates antibiotic efficacy in vivo in a manner consistent with the salt-dependent susceptibility observed in vitro. Together, these findings systematically quantify antibiotic susceptibility phenotypes across a broad compound panel and under environmental and genetic perturbations expected to alter OPG-associated periplasmic electrostatics and suggest new principles for antibiotic design and therapeutic optimization against multidrug-resistant pathogens.

  • Evaluation of Azithromycin-Bicarbonate against Multidrug-Resistant Pathogens in Topical Murine Models of Infection

    by Maya A. Farha, Megan M. Tu, Lindsey Carfrae, Ashelyn E. Sidders, Rodion Gordzevich, Adele Girgis-Gabardo, Julia P. Deisinger, J. Z. Alex Cheong, Ting Y. Wong, Mariel G. Escatte, et al.

    Multidrug-resistant pulmonary infections pose significant therapeutic challenges as treatment options continue to dwindle in the face of rising antimicrobial resistance. Similar challenges arise in the management of wound infections such as those resulting from burn and blast injuries, where resistant pathogens severely limit treatment options. These wounds are further complicated by high microbial loads that exacerbate tissue damage, delay healing, and increase the risk of systemic infection. The escalating threat of antimicrobial resistance highlights the urgent need for innovative therapeutic strategies. This study evaluates the therapeutic potential of a novel topical formulation, azithromycin-bicarbonate (AZM-BIC), for addressing drug-resistant infections in both pulmonary and wound settings. Using murine models of infection in bicarbonate-depleted environments, including lung, blast injury, and burn wound models, topical administration of AZM-BIC enabled the localized delivery of therapeutic concentrations of bicarbonate. In the pulmonary model, AZM-BIC significantly reduced the bacterial burden. In vitro and ex vivo studies revealed AZM-BIC's ability to inhibit biofilm formation, a critical factor in managing chronic infections. In wound infection models, AZM-BIC reduced the bacterial burden and enhanced wound healing. These findings establish AZM-BIC as a promising therapeutic approach, offering a targeted, effective solution for pulmonary infection management and wound care amid the growing threat of antimicrobial resistance. Furthermore, given that azithromycin is a well-established antibiotic and bicarbonate is a physiological component that is safe and well-tolerated, AZM-BIC represents a readily translatable strategy for clinical implementation.


  • Open Access

    Author Correction: Discovery and artificial intelligence-guided mechanistic elucidation of a narrow-spectrum antibiotic

    by Denise B. Catacutan, Vian Tran, Autumn Arnold, Jeremie Alexander, Gabriele Corso, Yeganeh Yousefi, Megan M. Tu, Stewart McLellan, Dominique Tertigas, Kimberly Corneil, et al.

  • Discovery and artificial intelligence-guided mechanistic elucidation of a narrow-spectrum antibiotic

    by Denise B. Catacutan, Vian Tran, Autumn Arnold, Jeremie Alexander, Gabriele Corso, Yeganeh Yousefi, Megan M. Tu, Stewart McLellan, Dominique Tertigas, Kimberly Corneil, et al.

    Current clinical antibiotics are largely broad-spectrum agents that can alter the gut microbiome and promote colonization by Enterobacteriaceae, which are often drug resistant. This includes adherent-invasive Escherichia coli (AIEC), particularly in patients with inflammatory bowel disease, in which dysbiosis creates a niche for this pathogen to colonize. There is an urgent and unmet need for novel narrow-spectrum and microbiome-sparing antibiotics. Here we screened 10,747 bioactive small molecules for antibacterial activity against AIEC and discovered enterololin, an antibacterial compound with targeted activity against Enterobacteriaceae species. Enterololin could overcome intrinsic and acquired resistance mechanisms in clinical isolates when combined with a subinhibitory concentration of SPR741, a polymyxin B analogue used here to increase outer membrane permeability in Gram-negative bacteria. Molecular substructure- and deep learning-guided mechanism-of-action investigations revealed that enterololin perturbs lipoprotein trafficking through a mechanism involving the LolCDE complex, laboratory-evolved resistant mutants predominantly mapped to lolC and lolE, with an in vitro frequency of resistance of ~10−8 to 10−7. Enterololin showed low mammalian cytotoxicity (HEK293 half-maximal inhibitory concentration ~100 µg ml−1) and suppressed AIEC infection in mouse models when administered in combination with SPR741, while largely preserving the overall microbiome composition. This study highlights the utility of deep learning methods for predicting molecular interactions and identifies a promising Enterobacteriaceae-specific antibacterial candidate for further development.


  • Identifying Modulators of the Post-Antibiotic Effect

    by Alexa L. Gilberti, Megan M. Tu, Kenneth Rachwalski, Madeeha I. Ali, Siobhan A. Cohen, Melike Akoglu, Alyssa C. Pollard-Kerning, Jinnette Tolentino Collado, Aya Sabbah, Franchesca Abou Said, et al.

    The postantibiotic effect (PAE) is the delay in bacterial regrowth following antibiotic removal. It has important implications for dosing regimens since drugs that have extended activity following their elimination can be dosed less frequently, widening the therapeutic window. While the PAE has been associated with target vulnerability and the rate of target turnover, little is known about the genetic components that modulate the PAE. Here, we developed a high-throughput assay to screen the Escherichia coli Keio collection of ∼4000 deletion strains, identifying genes that enhance the PAE for CHIR-090, an inhibitor of UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC). This screen revealed approximately 400 gene knockouts that enhanced the PAE of CHIR-090. The list of PAE enhancers was enriched for genes involved in transmembrane transport and outer membrane synthesis. Notably, deletion of the rfaE gene, which is involved in lipopolysaccharide (LPS) biosynthesis, increased the PAE of the LpxC inhibitors CHIR-090 and LPC-058 by 2 and 3 h, respectively. Consistent with this phenotype, cotreatment of wild-type E. coli with an RfaE inhibitor increased the PAE of CHIR-090 or LPC-058 by 1 h. To probe the mechanism of this interaction, we measured the rate of LpxC turnover and found that knocking out rfaE extended the half-life of LpxC by 2-fold, suggesting that disrupting RfaE increases the stability of LpxC, increasing target vulnerability and enhancing the PAE of LpxC inhibitors.


  • Open Access

    SyntheMol-RL: a flexible reinforcement learning framework for designing novel and synthesizable antibiotics

    by Kyle Swanson, Gary Liu, Denise B. Catacutan, Stewart McLellan, Autumn Arnold, Megan M. Tu, Eric D. Brown, James Zou, Jonathan M. Stokes

    The rise of antibiotic-resistant pathogens such as Staphylococcus aureus has created an urgent need for new antibiotics. Generative artificial intelligence (AI) has shown promise in drug discovery, but existing models often fail to propose compounds that are both effective and synthetically tractable. To address these challenges, we introduce SyntheMol-RL, a reinforcement learning-based generative model that can rapidly design synthetically accessible small molecule drug candidates from a massive chemical space of 46 billion compounds. SyntheMol-RL improves upon our prior Monte Carlo Tree Search (MCTS)-based SyntheMol model by generalizing across chemically similar building blocks and enabling multi-parameter optimization. We applied SyntheMol-RL to generate candidate antibiotics against S. aureus by optimizing for both antibacterial activity and aqueous solubility, and we found that SyntheMol-RL generated molecules with improved predicted properties compared to both the previous MCTS version of SyntheMol as well as an AI-based virtual screening baseline. We synthesized 79 SyntheMol-RL compounds that were unique relative to the training dataset and found that 13 showed potent in vitro activity, of which seven were structurally novel after detailed literature searches. Furthermore, one hit compound, synthecin, demonstrated efficacy in a murine wound infection model of methicillin-resistant S. aureus (MRSA). These results validate SyntheMol-RL’s ability to generate novel and synthetically accessible candidate antibiotics and position SyntheMol-RL as a powerful tool for drug design across therapeutic domains.


  • Exploiting the fitness cost of metallo-β-lactamase expression can overcome antibiotic resistance in bacterial pathogens

    by Megan M. Tu, Lindsey A. Carfrae, Kenneth Rachwalski, Shawn French, Denise Catacutan, Rodion Gordzevich, Craig R. MacNair, Melissa E. Speagle, Firas Werah, Jonathan M. Stokes, et al.

    Carbapenems are last-resort antibiotics for treating bacterial infections. The widespread acquisition of metallo-β-lactamases, such as VIM-2, contributes to the emergence of carbapenem-resistant pathogens, and currently, no metallo-β-lactamase inhibitors are available in the clinic. Here we show that bacteria expressing VIM-2 have impaired growth in zinc-deprived environments, including human serum and murine infection models. Using transcriptomic, genomic and chemical probes, we identified molecular pathways critical for VIM-2 expression under zinc limitation. In particular, disruption of envelope stress response pathways reduced the growth of VIM-2-expressing bacteria in vitro and in vivo. Furthermore, we showed that VIM-2 expression disrupts the integrity of the outer membrane, rendering VIM-2-expressing bacteria more susceptible to azithromycin. Using a systemic murine infection model, we showed azithromycin’s therapeutic potential against VIM-2-expressing pathogens. In all, our findings provide a framework to exploit the fitness trade-offs of resistance, potentially accelerating the discovery of additional treatments for infections caused by multidrug-resistant bacteria.


  • Open Access

    Hospital antimicrobial stewardship funding and resourcing impact on broad-spectrum antibiotic use: a cross-sectional study

    by Megan Tu, Zong Heng Shi, Valerie Leung, Kevin A Brown, Kevin L Schwartz, Nick Daneman, Bradley J Langford

    Background: Antimicrobial stewardship programs (ASPs) aim to mitigate antimicrobial resistance (AMR) by optimizing antibiotic use including reducing unnecessary broad-spectrum therapy. This study evaluates the impact of ASP funding and resources on the use of broad-spectrum antibiotics in Ontario hospitals. Methods: We conducted a cross-sectional study of antimicrobial use (AMU) across 63 Ontario hospitals from April 2020 to March 2023. The Ontario ASP Landscape Survey provided data on ASP resourcing and antibiotic utilization. The main outcome was the proportion of all antibiotics that were broad-spectrum, defined as: fluoroquinolones; third-generation cephalosporins; beta-lactam/beta-lactamase inhibitors; carbapenems; clindamycin; and parenteral vancomycin. Secondary outcomes included the proportions of individual antibiotic classes listed above and anti-pseudomonal agents. Statistical analysis involved logistic regression to determine the odds ratio (OR) of the association between ASP funding/resourcing and broad-spectrum antibiotic use. Results: Among 63 hospitals, 48 reported designated ASP funding/resources. Median broad-spectrum antibiotic use was 52.5%. ASP funding/resources was not associated with overall broad-spectrum antibiotic use (0.97, 95% CI: 0.75–1.25, P = 0.79). However, funding was associated with lower use of fluoroquinolones (OR 0.67, 95% CI: 0.46–0.96, P = 0.03), clindamycin (OR 0.69, 95% CI: 0.47–1.00, P = 0.05), and anti-pseudomonal agents (OR 0.76, 95% CI: 0.59–0.98, P = 0.03). Conclusion: The presence of designated funding and resources for hospital ASPs is linked to reduced use of specific broad-spectrum antibiotics but not overall broad-spectrum antibiotic use. Enhancing ASP resourcing may be an important factor in limiting targeted antibiotic use, thereby increasing the effectiveness of efforts to mitigate AMR.


  • Open Access

    The fitness cost of metallo-β-lactamase expression is a potential target for new therapeutic approaches to carbapenem resistance

    by Megan Tu, Lindsey Carfrae, Kenneth Rachwalski, Shawn French, Denise Catacutan, Rodion Gordzevich, Craig MacNair, Melissa Speagle, Firas Werah, Jonathan Stokes, et al.

    Carbapenem antibiotics represent the most reliable last-resort treatment for bacterial infections. The widespread acquisition of metallo-β-lactamases (MBLs), such as VIM-2, is a significant contributor to the emergence of carbapenem-resistant pathogens. The absence of clinically available MBL inhibitors necessitates the development of new approaches to treat carbapenem-resistant infections. Herein, we demonstrate that Enterobacteriaceae and Pseudomonas aeruginosa expressing VIM-2 have impaired growth in clinically relevant zinc-deprived environments, including human serum and murine infection models. Using transcriptomic, genomic, and chemical probes, we identified molecular pathways critical for VIM-2 expression in Escherichia coli under zinc limitation. Of particular note were envelope stress response pathways. Disruption of envelope stress response pathways significantly reduced the growth of VIM-2-expressing bacteria in vitro and in vivo. Furthermore, we demonstrated that VIM-2 expression disrupts the integrity of the outer membrane, rendering VIM-2-expressing bacteria more susceptible to antibiotics that are typically ineffective against Gram-negative bacteria, such as azithromycin. Accordingly, using a systemic murine infection model, we revealed that azithromycin has therapeutic potential in treating VIM-2-expressing Klebsiella pneumoniae. In all, our findings provide a framework to uncover and exploit the fitness trade-offs of resistance, potentially accelerating the discovery of novel treatments for multi-drug resistant bacteria.


  • Inhibiting fatty acid synthesis overcomes colistin resistance

    by Lindsey A. Carfrae, Kenneth Rachwalski, Shawn French, Rodion Gordzevich, Laura Seidel, Caressa N. Tsai, Megan M. Tu, Craig R. MacNair, Olga G. Ovchinnikova, Bradley R. Clarke, et al.

    Treating multidrug-resistant infections has increasingly relied on last-resort antibiotics, including polymyxins, for example colistin. As polymyxins are given routinely, the prevalence of their resistance is on the rise and increases mortality rates of sepsis patients. The global dissemination of plasmid-borne colistin resistance, driven by the emergence of mcr-1, threatens to diminish the therapeutic utility of polymyxins from an already shrinking antibiotic arsenal. Restoring sensitivity to polymyxins using combination therapy with sensitizing drugs is a promising approach to reviving its clinical utility. Here we describe the ability of the biotin biosynthesis inhibitor, MAC13772, to synergize with colistin exclusively against colistin-resistant bacteria. MAC13772 indirectly disrupts fatty acid synthesis (FAS) and restores sensitivity to the last-resort antibiotic, colistin. Accordingly, we found that combinations of colistin and other FAS inhibitors, cerulenin, triclosan and Debio1452-NH3, had broad potential against both chromosomal and plasmid-mediated colistin resistance in chequerboard and lysis assays. Furthermore, combination therapy with colistin and the clinically relevant FabI inhibitor, Debio1452-NH3, showed efficacy against mcr-1 positive Klebsiella pneumoniae and colistin-resistant Escherichia coli systemic infections in mice. Using chemical genomics, lipidomics and transcriptomics, we explored the mechanism of the interaction. We propose that inhibiting FAS restores colistin sensitivity by depleting lipid synthesis, leading to changes in phospholipid composition. In all, this work reveals a surprising link between FAS and colistin resistance.